Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion:</b> High radiation doses to ipsilateral NSC and contralateral SVZ could have a negative impact on overall survival in IDH-wild-type glioblastoma population.
|
30338243 |
2018 |
Glioblastoma Multiforme
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We analyzed The Cancer Genome Atlas dataset (TCGA) and identified a small group of IDH-mutant, WHO grade II-III astrocytomas (n = 14) with an unexpectedly poor prognosis characterized by a rapid progression to glioblastoma and death within 3 years of the initial diagnosis.
|
29741737 |
2018 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mutations in isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) were observed in GBM.
|
29662659 |
2018 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
We found that Creutzfeldt cell-rich GBMs were IDH-wildtype with no recurring genetic alterations.
|
29509313 |
2018 |
Glioblastoma Multiforme
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
• Significant correlation exists between radiological parameters such as volumetric and ADC values and major genomic profiles such as IDH mutation and ATRX loss status • Radiological parameters such as the ADC value were feasible predictors of glioblastoma patients' prognosis • Imaging features can predict major genomic profiles of the tumours and the prognosis of glioblastoma patients.
|
29721688 |
2018 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
<i>TERT</i> promoter mutations are selectively observed among 1p/19q-codeleted oligodendrogliomas and isocitrate dehydrogenase gene- <i>(IDH-)</i> wildtype glioblastoma (GBM).
|
29693015 |
2018 |
Glioblastoma Multiforme
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The purpose was to preoperatively predict IDH mutation status in GBM using multiregional radiomics features from multiparametric magnetic resonance imaging (MRI).
|
30426720 |
2018 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Differential expression of circRNAs may be associated with IDH-wt glioblastoma development and progression, and these circRNAs can be identified as biomarkers for prognosis prediction and targets for treatment.
|
29920451 |
2018 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
The recent 2016 WHO classification for CNS tumors categorizes diffuse glioma into two major types that include IDH wild-type glioblastoma, which is the predominant type and IDH-mutant glioblastoma, which is less common and displays better prognosis.
|
28730141 |
2017 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
H3-/IDH-wild type pediatric glioblastoma is comprised of molecularly and prognostically distinct subtypes with associated oncogenic drivers.
|
28401334 |
2017 |
Glioblastoma Multiforme
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The metabolic genes isocitrate dehydrogenase 1 (IDH1) and IDH2 are commonly mutated in low-grade glioma and in a subset of glioblastoma.
|
28980701 |
2017 |
Glioblastoma Multiforme
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
From 578 total gliomas tested, 88 were IDH-mutant DA/AA/GBMs and 11 IDH-mutant tumors were in persons age 55 and older.
|
28110298 |
2017 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
All patients were diagnosed with IDH-wild type glioblastoma according to pathological criteria.
|
29212499 |
2017 |
Glioblastoma Multiforme
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In low-grade glioma (LGG) and glioblastoma cohorts of TCGA, significantly higher PD-L1 gene expression levels were evident in IDH-wt compared with IDH-mut samples (LGG: N = 516; P = 1.933e-11, GBM: N = 161; P < 0.009).
|
28531337 |
2017 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
For patients with GBM, no difference in survival was observed (p = .10).MGMT and IDH status affected outcome.
|
28675067 |
2017 |
Glioblastoma Multiforme
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Epidermal growth factor receptor (EGFR) is a major oncogenic driver in glioblastoma (GBM) without mutations in the isocitrate dehydrogenase gene (IDH-wildtype).
|
28765916 |
2017 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
We identified a subset of tumors (n = 18, 8.8% of high-grade gliomas) exhibiting moderate-to-strong immunoreactivity that enriched for the IDH-wild-type glioblastoma variants gliosarcoma (n = 10) and the newly described epithelioid glioblastoma (n = 4).
|
28789475 |
2017 |
Glioblastoma Multiforme
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
IDH1<sup>R132H</sup>-negative GBM showed higher ALK expression compared with IDH-mutant GBM (65.2% vs 20%).
|
27993946 |
2017 |
Glioblastoma Multiforme
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Rapid progression to glioblastoma in a subset of IDH-mutated astrocytomas: a genome-wide analysis.
|
28421459 |
2017 |
Glioblastoma Multiforme
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Addition of 2-HG to glioblastoma cultures recapitulates the effects of the IDH mutation on intrinsic apoptosis, shuts down oxidative phosphorylation and reduces ATP levels in glioblastoma cells.
|
29057925 |
2017 |
Glioblastoma Multiforme
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In the absence of IDH mutation, several genes associated with metabolism are differentially expressed in these subtypes of primary GBM, implicating metabolic reprogramming occurs in tumor microenvironment.
|
28278055 |
2017 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Oncogenic mutations in two isocitrate dehydrogenase (IDH)-encoding genes (IDH1 and IDH2) have been identified in acute myelogenous leukemia, low-grade glioma, and secondary glioblastoma (GBM).
|
28564604 |
2017 |
Glioblastoma Multiforme
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The metabolomics data were tested for correlation with glioma grade (high vs low), glioblastoma (GBM) versus malignant gliomas, and IDH mutation status.
|
26967252 |
2016 |
Glioblastoma Multiforme
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Finally, five tumors were IDH wild-type (IDHwt) and had chromosome seven gains, chromosome 10 losses, and homozygous 9p deletions (CDKN2A), alterations typical of IDHwt (primary) GBM.
|
26757882 |
2016 |
Glioblastoma Multiforme
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Among the WHO grade II and III gliomas, IDH1 mutations were significantly associated with preoperative seizures, but no significant relationship between IDH mutations and preoperative seizures was found with glioblastoma multiforme.
|
27406953 |
2016 |